Ampio Pharmaceuticals, Inc. (AMPE) 10-K Annual Report March 2021

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
Document And Entity Information - USD ($) $ in Millions	Dec. 31, 2020	Feb. 16, 2021	Jun. 30, 2020
Document And Entity Information [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Document Transition Report	false
Entity File Number	001-35182
Entity Registrant Name	AMPIO PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-0179592
Entity Address, Address Line One	373 Inverness Parkway
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Englewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80112
City Area Code	720
Local Phone Number	437-6500
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	AMPE
Security Exchange Name	NYSEAMER
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 106.2
Entity Common Stock, Shares Outstanding		195,629,128
Entity Central Index Key	0001411906
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1411906/000155837021002314/ampe-20201231x10k.htm

View differences made from one year to another to evaluate Ampio Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Ampio Pharmaceuticals, Inc..

Continue

Assess how Ampio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Ampio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Legal

Other

Filter Subcategory:

All

Expense

Other

Inside Ampio Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial - Shares Highlight
Our shelf registration statement, which was declared effective by the SEC in May 2020, provides us with the ability to sell up to an aggregate amount of $100.0 million of shares of common stock, preferred stock, debt securities, warrants and units, or any combination thereof, less any sales from the ATM equity offering program that occurred prior to May 6, 2020, which was the effective date of the shelf registration statement.

Financial - Expense Highlight
Research and development costs are summarized as follows and exclude an allocation of general and administrative expenses: 2020 Period Compared to 2019 Period Research and development costs decreased approximately $3.4 million, or 27.3%, for the 2020 period compared to the 2019 period.
Financial - Expense Highlight
General and administrative expenses are summarized as follows: 2020 Period Compared to 2019 Period General and administrative costs increased $708,000, or 11.9%, for the 2020 period compared to the 2019 period.
Financial - Expense Highlight
The pharmaceutical market is a highly competitive industry with strict regulations that are unpredictable in nature, time intensive and costly.
Other - Other Highlight
This could lead to impairment or other charges, which could materially affect our balance sheet and operating results.
Financial - Shares
Based on our current cash...Read more
Financial - Expense
In general, we believe that...Read more
Financial - Expense
Insurance Insurance expense increased $449,000,...Read more
Financial - Expense
Clinical trial and sponsored research...Read more
Legal - Other
The decrease in legal fees...Read more
Financial - Expense
Regulatory/FDA Regulatory/FDA expenses decreased $158,000,...Read more
Financial - Shares
The exercise of outstanding warrants...Read more
Financial - Expense
Laboratory Laboratory expenses decreased $151,000,...Read more
Other - Other
The continued state and local...Read more
Legal - Other
Professional fees Professional fees decreased...Read more
Other - Other
In April 2020, we received...Read more
Financial - Expense
Research and development costs with...Read more
Financial - Shares
For example, despite the historically...Read more
Other - Other
We anticipate that we will...Read more
Other - Other
Moving forward, we will continue...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Ampio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 4.1: Instruments Defining The Rights Of Security Holders, Including Indentures

Exhibit 10.4: Material Contract

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Ticker: AMPE
CIK: 1411906
Form Type: 10-K Annual Report
Accession Number: 0001558370-21-002314
Submitted to the SEC: Wed Mar 03 2021 4:11:50 PM EST
Accepted by the SEC: Wed Mar 03 2021
Period: Thursday, December 31, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/ampe/0001558370-21-002314.htm

Ampio Pharmaceuticals, Inc. (AMPE) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2020

SEC Filings

AMPE Valuations

AMPE Annual Reports

AMPE Quarterly Reports

AMPE Corporate News